Real-world use of bone-modifying agents (BMA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the US. Real world outcomes of 177Lu-PSMA-617 PSMA in a racially diverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results